CSL (CSLLY) 1-Year Sharpe Ratio: -2.04 (As of Jul. 05, 2026)


CSLLY CSL Ltd CSLLY
73 GF Score
Price $20.49
GF Value $48.31
Valuation Significantly Undervalued
! 7 Warning Signs
View Full Analysis

What is CSL 1-Year Sharpe Ratio?

CSL CSLLY -0.07% 73 1-Year Sharpe Ratio is -2.04 as of Jul. 05, 2026. GuruFocus rates CSLLY with a GF Score™ of 73/100 and a GF Value™ of $48.31 (Significantly Undervalued). The stock has 7 warning signs investors should review.

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-07-05), CSL's 1-Year Sharpe Ratio is -2.04.

CSL  (OTCPK:CSLLY) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

CSL 1-Year Sharpe Ratio Related Terms

CSLLY vs VRTX, REGN, ALNY: 1-Year Sharpe Ratio Comparison

For the Biotechnology subindustry, CSL's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CSL 1-Year Sharpe Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CSL's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where CSL's 1-Year Sharpe Ratio falls into.


CSLLY
73GF Score
CSL Ltd CSLLY
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CSL 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Frequently Asked Questions Learn more about 1-Year Sharpe Ratio →
What does a 1-Year Sharpe Ratio of -2.04 mean?
CSL (CSLLY) has a 1-Year Sharpe Ratio of -2.04 as of Jul. 05, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for CSL and its competitors.
Is CSL's 1-Year Sharpe Ratio too high?
CSL's current 1-Year Sharpe Ratio is -2.04. Overall, CSL has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's 1-Year Sharpe Ratio compare to VRTX and REGN?
CSL's 1-Year Sharpe Ratio of -2.04 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Biotechnology company?
A good 1-Year Sharpe Ratio depends on the Biotechnology industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for CSL and its competitors. CSL's current 1-Year Sharpe Ratio is -2.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (CSLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $48.31, compared to a current price of $20.49 — trading 57.6% below its estimated fair value. The current 1-Year Sharpe Ratio is -2.04. CSL's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For CSL (CSLLY), the current 1-Year Sharpe Ratio is -2.04 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CSL (CSLLY) Overvalued in 2026?

Based on GuruFocus' analysis, CSL stock appears to be undervalued. The current stock price of $20.49 is trading 57.6% below its estimated GF Value™ of $48.31. GuruFocus considers CSL to be Significantly Undervalued.

Key valuation signals for CSLLY:

  • 1-Year Sharpe Ratio: -2.04
  • GF Value™: $48.31 vs. price of $20.49 (57.6% below fair value)
  • GF Score™: 73/100 with 7 warning signs

No single metric tells the full story. See the CSLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CSL Business Description

Address 655 Elizabeth Street, Melbourne, VIC, AUS, 3000
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
73GF Score

Get the complete analysis for CSLLY

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.49
Price
$48.31
GF Value